Reviews16 May 2006
    Author, Article, and Disclosure Information

    Osteonecrosis of the jaws is a recently described adverse side effect of bisphosphonate therapy. Patients with multiple myeloma and metastatic carcinoma to the skeleton who are receiving intravenous, nitrogen-containing bisphosphonates are at greatest risk for osteonecrosis of the jaws; these patients represent 94% of published cases. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60% of cases are preceded by a dental surgical procedure. Oversuppression of bone turnover is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. All sites of potential jaw infection should be eliminated before bisphosphonate therapy is initiated in these patients to reduce the necessity of subsequent dentoalveolar surgery. Conservative débridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses, and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition. The degree of risk for osteonecrosis in patients taking oral bisphosphonates, such as alendronate, for osteoporosis is uncertain and warrants careful monitoring.

    References

    • 1. Fleisch HBisphosphonates: mechanisms of action. Endocr Rev1998;19:80-100. [PMID: 9494781] CrossrefMedlineGoogle Scholar
    • 2. Russell RGCroucher PIRogers MJBisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int1999;9 Suppl 2 S66-80. [PMID: 10525729] CrossrefMedlineGoogle Scholar
    • 3. Lin JHRussell GGertz BPharmacokinetics of alendronate: an overview. Int J Clin PractSuppl 1999;101:18-26. [PMID: 12669737] MedlineGoogle Scholar
    • 4. Green JRBisphosphonates: preclinical review. Oncologist2004;9 Suppl 4 3-13. [PMID: 12584689] CrossrefMedlineGoogle Scholar
    • 5. Hughes DEMacDonald BRRussell RGGowen MInhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest1989;83:1930-5. [PMID: 2524504] CrossrefMedlineGoogle Scholar
    • 6. Vitté CFleisch HGuenther HLBisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology1996;137:2324-33. [PMID: 8641182] CrossrefMedlineGoogle Scholar
    • 7. Santini DVespasiani Gentilucci UVincenzi BPicardi AVasaturo FLa Cesa Aet alThe antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol2003;14:1468-76. [PMID: 14504045] CrossrefMedlineGoogle Scholar
    • 8. Wood JBonjean KRuetz SBellahcène ADevy LFoidart JMet alNovel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther2002;302:1055-61. [PMID: 12183663] CrossrefMedlineGoogle Scholar
    • 9. Vincenzi BSantini DDicuonzo GBattistoni FGavasci MLa Cesa Aet alZoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res2005;25:144-51. [PMID: 15767788] CrossrefMedlineGoogle Scholar
    • 10. Kunzmann VBauer EFeurle JWeissinger FTony HPWilhelm MStimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood2000;96:384-92. [PMID: 10887096] CrossrefMedlineGoogle Scholar
    • 11. Mariani SMuraro MPantaleoni FFiore FNuschak BPeola Set alEffector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia2005;19:664-70. [PMID: 15744346] CrossrefMedlineGoogle Scholar
    • 12. Lipton ATheriault RLHortobagyi GNSimeone JKnight RDMellars Ket alPamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:1082-90. [PMID: 10699899] CrossrefMedlineGoogle Scholar
    • 13. Berenson JRRosen LSHowell APorter LColeman REMorley Wet alZoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer2001;91:1191-200. [PMID: 11283917] CrossrefMedlineGoogle Scholar
    • 14. Saad FClinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer2005;4:31-7. [PMID: 15992459] CrossrefMedlineGoogle Scholar
    • 15. Mashiba TMori SBurr DBKomatsubara SCao YManabe Tet alThe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab2005;23 Suppl 36-42. [PMID: 15984412] CrossrefMedlineGoogle Scholar
    • 16. Weinstein RSTrue strength. J Bone Miner Res2000;15:621-5. [PMID: 10780853] CrossrefMedlineGoogle Scholar
    • 17. Whyte MPWenkert DClements KLMcAlister WHMumm SBisphosphonate-induced osteopetrosis. N Engl J Med2003;349:457-63. [PMID: 12890844] CrossrefMedlineGoogle Scholar
    • 18. Odvina CVZerwekh JERao DSMaalouf NGottschalk FAPak CYSeverely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab2005;90:1294-301. [PMID: 15598694] CrossrefMedlineGoogle Scholar
    • 19. Ott SMFractures after long-term alendronate therapy [Letter]. J Clin Endocrinol Metab2001;86:1835-6. [PMID: 11297626] CrossrefMedlineGoogle Scholar
    • 20. Ott SMLong-term safety of bisphosphonates. J Clin Endocrinol Metab2005;90:1897-9. [PMID: 15758064] CrossrefMedlineGoogle Scholar
    • 21. Goodship AEWalker PCMcNally DChambers TGreen JRUse of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol1994;5 Suppl 7 S53-5. [PMID: 7873463] MedlineGoogle Scholar
    • 22. Li CMori SLi JKaji YAkiyama TKawanishi Jet alLong-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res2001;16:429-36. [PMID: 11277259] CrossrefMedlineGoogle Scholar
    • 23. Gonzalez-Moles MABagan-Sebastian JVAlendronate-related oral mucosa ulcerations. J Oral Pathol Med2000;29:514-8. [PMID: 11048968] CrossrefMedlineGoogle Scholar
    • 24. Demerjian NBolla GSpreux ASevere oral ulcerations induced by alendronate. Clin Rheumatol1999;18:349-50. [PMID: 10468180] CrossrefMedlineGoogle Scholar
    • 25. Ruggiero SLMehrotra BRosenberg TJEngroff SLOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg2004;62:527-34. [PMID: 15122554] CrossrefMedlineGoogle Scholar
    • 26. Estilo CSVan Poznak CHWilliams TEvtimovska ETkach LHalpern JLet alOsteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study [Abstract]. Proc Am Soc Clin Oncol2004;22:750. MedlineGoogle Scholar
    • 27. Marx RESawatari YFortin MBroumand VBisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg2005;63:1567-75. [PMID: 16243172] CrossrefMedlineGoogle Scholar
    • 28. Migliorati CASchubert MMPeterson DESeneda LMBisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer2005;104:83-93. [PMID: 15929121] CrossrefMedlineGoogle Scholar
    • 29. Purcell PMBoyd IWBisphosphonates and osteonecrosis of the jaw. Med J Aust2005;182:417-8. [PMID: 15850440] CrossrefMedlineGoogle Scholar
    • 30. Bagan JVJimenez YMurillo JHernandez SPoveda RSanchis JMet alJaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. Oral Oncol2006;42:327-9. [PMID: 16275156] CrossrefMedlineGoogle Scholar
    • 31. Pires FRMiranda ACardoso ESCardoso ASFregnani ERPereira CMet alOral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis2005;11:365-9. [PMID: 16269027] CrossrefMedlineGoogle Scholar
    • 32. Bamias AKastritis EBamia CMoulopoulos LAMelakopoulos IBozas Get alOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol2005;23:8580-7. [PMID: 16314620] CrossrefMedlineGoogle Scholar
    • 33. Melo MDObeid GOsteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc2005;136:1675-81. [PMID: 16383049] CrossrefMedlineGoogle Scholar
    • 34. Zarychanski RElphee EWalton PJohnston JOsteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol2006;81:73-5. [PMID: 16369966] CrossrefMedlineGoogle Scholar
    • 35. Wang JGoodger NMPogrel MAOsteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg2003;61:1104-7. [PMID: 12966490] CrossrefMedlineGoogle Scholar
    • 36. Lugassy GShaham RNemets ABen-Dor DNahlieli OSevere osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity [Letter]. Am J Med2004;117:440-1. [PMID: 15380503] CrossrefMedlineGoogle Scholar
    • 37. Vannucchi AMFicarra GAntonioli EBosi AOsteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol2005;128:738. [PMID: 15755276] CrossrefMedlineGoogle Scholar
    • 38. Maerevoet MMartin CDuck LOsteonecrosis of the jaw and bisphosphonates [Letter]. N Engl J Med2005;353:99-102. [PMID: 16003838] CrossrefMedlineGoogle Scholar
    • 39. Viale PHLin AExposed bone in oral cavities. Clin J Oncol Nurs2005;9:355-7. [PMID: 15973847] CrossrefMedlineGoogle Scholar
    • 40. Carter GGoss ANDoecke CBisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust2005;182:413-5. [PMID: 15850439] CrossrefMedlineGoogle Scholar
    • 41. Philipone ENonhealing extraction site. Gen Dent2005;53:161, 163. [PMID: 15833019] MedlineGoogle Scholar
    • 42. Throndson RRHealy SMZwickey MRBisphosphonate-induced osteonecrosis of the jaws. Tex Dent J2005;122:960-5. [PMID: 16320503] MedlineGoogle Scholar
    • 43. Markiewicz MRMargarone JECampbell JHAguirre ABisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc2005;136:1669-74. [PMID: 16383048] CrossrefMedlineGoogle Scholar
    • 44. Polizzotto MNCousins VSchwarer APBisphosphonate-associated osteonecrosis of the auditory canal [Letter]. Br J Haematol2006;132:114. [PMID: 16371027] CrossrefMedlineGoogle Scholar
    • 45. Sarathy APBourgeois SLGoodell GGBisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod2005;31:759-63. [PMID: 16186759] CrossrefMedlineGoogle Scholar
    • 46. Merigo EManfredi MMeleti MCorradi DVescovi PJaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med2005;34:613-7. [PMID: 16202082] CrossrefMedlineGoogle Scholar
    • 47. Katz HEndodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod2005;31:831-4. [PMID: 16249730] CrossrefMedlineGoogle Scholar
    • 48. Gibbs SDO'Grady JSeymour JFPrince HMBisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention [Letter]. Med J Aust2005;183:549-50. [PMID: 16296983] CrossrefMedlineGoogle Scholar
    • 49. Lenz JHSteiner-Krammer BSchmidt WFietkau RMueller PCGundlach KKDoes avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg2005;33:395-403. [PMID: 16253510] CrossrefMedlineGoogle Scholar
    • 50. Yeo ACLye KWPoon CYBisphosphonate-related osteonecrosis of the jaws. Singapore Dent J2005;27:36-40. [PMID: 16438267] MedlineGoogle Scholar
    • 51. Marunick MMiller RGordon SAdverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc2005;87:44-9. [PMID: 16372548] MedlineGoogle Scholar
    • 52. Sitters MACaldwell CSBisphosphonates, dental care and osteonecrosis of the jaws. Tex Dent J2005;122:968-72. [PMID: 16320504] MedlineGoogle Scholar
    • 53. Ficarra GBeninati FRubino IVannucchi ALongo GTonelli Pet alOsteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol2005;32:1123-8. [PMID: 16212571] CrossrefMedlineGoogle Scholar
    • 54. Pastor-Zuazaga DGaratea-Crelgo JMartino-Gorbea REtayo-Pérez ASebastián-López COsteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal2006;11:76-9. [PMID: 16388300] MedlineGoogle Scholar
    • 55. Starck WJEpker BNFailure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants1995;10:74-8. [PMID: 7615320] MedlineGoogle Scholar
    • 56. Marx REOsteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg1983;41:283-8. [PMID: 6572704] CrossrefMedlineGoogle Scholar
    • 57. Thorn JJHansen HSSpecht LBastholt LOsteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg2000;58:1088-93; discussion 1093-5. [PMID: 11021701] CrossrefMedlineGoogle Scholar
    • 58. Reuther TSchuster TMende UKübler AOsteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients—a report of a thirty year retrospective review. Int J Oral Maxillofac Surg2003;32:289-95. [PMID: 12767877] CrossrefMedlineGoogle Scholar
    • 59. Reid IRBrown JPBurckhardt PHorowitz ZRichardson PTrechsel Uet alIntravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med2002;346:653-61. [PMID: 11870242] CrossrefMedlineGoogle Scholar
    • 60. Jones JR, Lehtinen T, Riphagen FE, von Roemeling R. Adverse event (AE) reporting of oral clodronate with emphasis on osteonecrosis of the jaws [Abstract]. Presented at the Annual Meeting of the American Society for Clinical Oncology, 2005. Abstract 799. Google Scholar
    • 61. Durie BGKatz MCrowley JOsteonecrosis of the jaw and bisphosphonates [Letter]. N Engl J Med2005;353:99-102. [PMID: 16000365] CrossrefMedlineGoogle Scholar
    • 62. Drexler HCRisau WKonerding MAInhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J2000;14:65-77. [PMID: 10627281] CrossrefMedlineGoogle Scholar
    • 63. Rajkumar SVHayman SGertz MADispenzieri ALacy MQGreipp PRet alCombination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol2002;20:4319-23. [PMID: 12409330] CrossrefMedlineGoogle Scholar
    • 64. Peters ELovas GLWysocki GPLingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol1993;75:739-43. [PMID: 8515988] CrossrefMedlineGoogle Scholar
    • 65. Ruggiero SGralow JMarx REHoff AOSchubert MMHuryn JMet alPractical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaws in patients with cancer. Journal of Oncology Practice2006;2:7-14. CrossrefMedlineGoogle Scholar
    • 66. Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004. Professional Education Material. East Hanover, NJ: Novartis; 2004. Google Scholar
    • 67. Woo SBMatin KOff-site dental evaluation program for prospective bone marrow transplant recipients. J Am Dent Assoc1997;128:189-93. [PMID: 9037972] CrossrefMedlineGoogle Scholar
    • 68. Bishay NPetrikowski CGMaxymiw WGLee LWood REOptimum dental radiography in bone marrow transplant patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod1999;87:375-9. [PMID: 10102604] CrossrefMedlineGoogle Scholar
    • 69. Carter GDGoss ANBisphosphonates and avascular necrosis of the jaws [Letter]. Aust Dent J2003;48:268. [PMID: 14738134] MedlineGoogle Scholar
    • 70. McCloskey EVDunn JAKanis JAMacLennan ICDrayson MTLong-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol2001;113:1035-43. [PMID: 11442499] CrossrefMedlineGoogle Scholar
    • 71. Pectasides DNikolaou MFarmakis DKanakis IGaglia AKountourakis Pet alClinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res2005;25:1457-63. [PMID: 15865105] MedlineGoogle Scholar